The round closed fast. Isomorphic announced the $5 billion Series C on Tuesday, November 17, describing it as oversubscribed, with Greenoaks and Sequoia Capital sharing the lead. Andreessen Horowitz joined as a new investor, Alphabet put in more money, and every existing backer returned — Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose a valuation.

Six months, $7 billion#

The pace is the story as much as the size. Isomorphic raised $2.1 billion in May 2026 in a Series B led by Thrive Capital, and $600 million in March 2025, also led by Thrive. The new round brings its external fundraising to $7.7 billion in under two years — $7.1 billion of it in 2026 alone. For a company with no drug in human trials yet, that is an extraordinary vote of confidence, and it makes Isomorphic one of the best-capitalized private AI companies in the world.

It also fits Alphabet’s playbook for its big bets. Waymo raised $16 billion at a $126 billion valuation earlier this year, and Isomorphic is now the second Alphabet-linked company to command a pharma- or auto-scale war chest on the strength of AI models rather than products on the market. The October funding talks — which reportedly priced Isomorphic at $40 billion or more — clearly found their audience: this round’s investor list reads like a roll call of the firms that have decided AI-designed medicine is a matter of when, not if.

What IsoDDE actually does#

IsoDDE is Isomorphic’s proprietary drug-design engine: a suite of simulation models that work across therapeutic areas and drug types, exploring vast chemical spaces to design molecules with the properties a drug needs. Paired with agents that reason over complex biological systems, the models are meant to turn drug discovery from a slow, failure-prone search into something closer to engineering — design the molecule on a computer, then test it in the lab.

The engine descends from DeepMind’s AlphaFold, the Nobel-winning system for predicting protein structures, and Isomorphic says the simulation models inside IsoDDE now push predictions toward experimental accuracy. The company reports positive preclinical results from internal programs in oncology and immunology, and from partnered programs — results it says put it in position to enter the clinic. Those results are company-reported, not independently verified, and preclinical success is a long way from a medicine.

Illustration of a drug-design engine: molecular structures flowing through a neural-network lattice into a glowing candidate molecule.
From chemical space to candidate: IsoDDE explores vast molecular spaces to design drug-like molecules. Graphic: AI Frontier Post.

The money goes to trials, not just models#

What the $5 billion buys, according to the announcement, is the next stage of the pipeline rather than more of the same. The company will keep maturing IsoDDE and push into new areas of biology, build a partner ecosystem around understanding disease mechanisms, and — the telling part — construct the global infrastructure for AI-led bioengineering, including the translational and clinical development machinery its candidates need to reach patients.

That shift matters because the bottleneck in AI drug discovery is no longer generating candidates. It is proving them. No AI-designed medicine has yet reached the market, and the clinic is where every model-first claim meets its hardest test: human biology, regulators, and years of trials. Isomorphic gave no date for its first human trial in the announcement, and the money will be judged on whether it produces one.

A vial and a petri dish on a laboratory bench at sunrise, with a modern research building behind.
The next test is clinical: the new money builds the infrastructure to take candidates from the lab to patients. Graphic: AI Frontier Post.

What to watch#

First, the trial itself: when Isomorphic’s first candidate enters human testing, and how much the company discloses about it, will say more than any funding round. Second, the valuation: October’s talks reportedly put the company at $40 billion or more, and the absence of a number in today’s announcement leaves the market guessing whether the price went up, down, or was simply kept private. Third, the partner pipeline: collaborations with Eli Lilly, Novartis and Johnson & Johnson, announced over the past two years, are where outside validation would show up first — in milestones reached, not press releases. And fourth, the field: with $7 billion raised in a single year, Isomorphic is now the biggest test of whether AI can design medicines at all. The models have the money. The clinic gets the verdict.

Sources: Isomorphic Labs (PR Newswire) (November 17, 2026, the announcement); Tech.eu (November 17, 2026); Unite.AI (November 17, 2026). See also our October coverage of the funding talks.